| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Teva CEO 'proud' of pipeline buzz as innovative-generics hybrid rolls out 1st R&D day | ||
| Fr | Bavarian Nordic C-suite stability in question as CFO steps down amid Q3 beat | ||
| Fr | Fierce Pharma Asia-China's Big Pharma ambition; Treasury's China crackdown; Takeda's narcolepsy launch | ||
| Fr | Sanofi teams with British comic Beano for Type 1 diabetes education push | ||
| Fr | Novo amps up Wegovy marketing with DJ Khaled spinning his weight-loss tale | ||
| 12.11. | Pharmas should stay agile as Democrats amp up scrutiny over Trump's MFN deals | ||
| 12.11. | FDA appears to pause controversial speedy review program, complete response letter disclosures | ||
| 12.11. | Orzeyful's 'lighter' DEA schedule paves way for Takeda's first-in-class narcolepsy launch | ||
| 12.11. | Radiopharma player PharmaLogic snaps up Lantheus' CDMO business, plant as Curium acquisition advances | ||
| 12.11. | AI models from Google, Anthropic and more lean on recommending promoted drugs: study | ||
| 11.11. | FDA cites record request breakdowns in trio of warning letters to API makers | ||
| 11.11. | Legend Biotech shares fall 16% after first earnings report under new CEO | ||
| 11.11. | BioNTech pays $205M for FDA voucher to speed up 'late-stage oncology pipeline' | ||
| 11.11. | Aurobindo unit Eugia recalls antibiotic lot, citing glass particle concerns | ||
| 10.11. | ImmunityBio juggles phase 3 win and 20% stock crash en route to Anktiva front-line expansion | ||
| 10.11. | Summit sheds commercial leaders ahead of ivonescimab's FDA decision | ||
| 10.11. | J&J readies Caplyta for FDA label expansion after 2nd phase 3 win in bipolar mania | ||
| 10.11. | After court win, WuXi AppTec scores removal from US list of Chinese military companies | ||
| 10.11. | FDA orders new eye risk be listed on a dozen GLP-1s, including Novo's Ozempic, Lilly's Zepbound | ||
| 10.11. | Phillips Medisize strikes deal to expand UK inhalation production | ||
| 10.11. | Vertex lays off 78 Crinetics staffers amid $10B integration | ||
| 10.11. | Insulet, Marvel Comics smash diabetes stigma with new Omnipod-powered superhero | ||
| 10.11. | Bayer brings factor XIa to US stroke prevention with FDA nod for 1st-in-class asundexian | ||
| 09.11. | Veradermics wraps phase 3 program in men with 'better-than-expected' hair growth at 1 year | ||
| 09.11. | FDA opens safety probe into Novartis' Zolgensma over potential tumor risks |